Product
Help
Pricing
About
Jobs
Log in
Get started
Work
Add to collection
Nintedanib in the treatment of idiopathic pulmonary fibrosis
HTML
Details
Locations
Year:
2015
Type:
review
Source:
Therapeutic Advances in Respiratory Disease
DOI:
10.1177/1753465815579365
Authors:
Mariano E. Mazzei,
Luca Richeldi,
Harold R. Collard
Institutions:
Universidad de Buenos Aires,
National Institute for Health and Care Research,
NIHR Southampton Respiratory Biomedical Research Unit,
University of Southampton,
University of California, San Francisco
Language:
English
Topic:
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Subfield:
Pulmonary and Respiratory Medicine
Field:
Medicine
Domain:
Health Sciences
Keywords:
nintedanib,
idiopathic pulmonary fibrosis,
tyrosine kinase inhibitors,
disease progression,
forced vital capacity decline,
fibroblast proliferation and migration,
extracellular matrix secretion,
INPULSIS trials,
drug safety and efficacy
show all 9
SDG:
Good health and well-being
Open Access status:
closed
Funders:
Pfizer,
AstraZeneca,
GlaxoSmithKline,
Sanofi,
Gilead Sciences,
FibroGen,
Shionogi,
National Institutes of Health,
Genentech,
National Heart, Lung, and Blood Institute
show all 10
OpenAlex ID:
W2119639538
FWCI:
1.803
Cites:
27
Cited by:
87
Related to:
10